NASDAQ: SSKNStrata Skin Sciences Inc Stock
$0.59+0.00 (+0%)
Updated Sep 27, 2023
SSKN Price
$0.59
Fair Value Price
$0.68
Market Cap
$20.74M
52 Week Low
$0.45
52 Week High
$1.39
P/E
-2.83x
P/B
1.23x
P/S
0.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$35.83M
Earnings
-$7.14M
Gross Margin
59.6%
Operating Margin
-16.67%
Profit Margin
-19.9%
Debt to Equity
2.27
Operating Cash Flow
-$2M
Beta
0.63
Next Earnings
Nov 7, 2023
Ex-Dividend
N/A
Next Dividend
N/A
SSKN Overview
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SSKN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SSKN ($0.59) is undervalued by 12% relative to our estimate of its Fair Value price of $0.68 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SSKN ($0.59) is not significantly undervalued (12%) relative to our estimate of its Fair Value price of $0.68 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SSKN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SSKN due diligence checks available for Premium users.
Be the first to know about important SSKN news, forecast changes, insider trades & much more!
SSKN News
Valuation
SSKN fair value
Fair Value of SSKN stock based on Discounted Cash Flow (DCF)
Price
$0.59
Fair Value
$0.68
Undervalued by
12.60%
SSKN ($0.59) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SSKN ($0.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SSKN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SSKN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.83x
Industry
48.19x
Market
13.45x
SSKN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.23x
Industry
3.46x
SSKN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SSKN's financial health
Profit margin
Revenue
$8.3M
Net Income
-$3.1M
Profit Margin
-38.2%
SSKN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SSKN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$55.2M
Liabilities
$38.3M
Debt to equity
2.27
SSKN's short-term assets ($21.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SSKN's long-term liabilities ($24.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SSKN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SSKN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$175.0k
Investing
-$931.0k
Financing
$0.0
SSKN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SSKN vs Medical Device Stocks
Strata Skin Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.